Medicare Weighs Coverage for Trusted Breast Cancer Test, Sparking Concern From Doctors
A private advisory panel’s recommendation against reimbursing for crucial biomarker testing has patients and physicians bracing for what could be a devastating loss of access.
LeeAnne Loney found herself facing an agonizing choice in the summer of 2024. Like millions of American women navigating a breast cancer diagnosis, she needed answers—fast. The biomarker test her doctors recommended could mean the difference between enduring grueling chemotherapy or pursuing a more targeted, less invasive treatment path. But when she looked at the potential out-of-pocket costs, the weight of that decision became almost unbearable.
Now, that same test—and others like it—could be out of reach for millions of Medicare beneficiaries across the United States.
A private company that advises the Centers for Medicare & Medicaid Services (CMS) has recommended against reimbursing for these biomarker tests. The decision has sparked a fierce backlash from cancer specialists, patient advocacy groups, and lawmakers who argue that restricting access to these life-saving tools would effectively turn back the clock on decades of progress in precision oncology.
what are biomarker tests and why do they matter?
For the uninitiated, biomarker testing—also known as genomic or molecular testing—analyzes tissue samples to identify specific genetic mutations within a tumor. These tests help oncologists determine whether a patient’s cancer is likely to respond to chemotherapy, targeted therapies, or immunotherapy.
In breast cancer alone, biomarker tests like Oncotype DX and MammaPrint have become standard of care. They provide critical decision-guidance regarding the medical necessity of chemotherapy, sparing countless women from unnecessary side effects while ensuring those who need aggressive treatment receive it promptly.
The stakes couldn’t be higher. Biomarker testing for breast cancer patients has been hailed by oncologists as nothing short of revolutionary—a tool that moves cancer care from a one-size-fits-all approach to truly personalized medicine.
what the proposed change means for patients
If the recommendation moves forward, millions of women could lose Medicare coverage for these tests. That doesn’t mean the tests would become unavailable—it means patients would have to pay for them out of pocket. And the costs are staggering.
Depending on the specific test and laboratory, biomarker panels can run anywhere from $3,000 to $6,000 or more. For seniors living on fixed incomes, that’s simply not an option.
“This isn’t about a luxury test,” one oncology nurse practitioner told Voxenews. “This is about whether a 68-year-old grandmother in rural Kansas gets the information she needs to make the most informed decision about her own life. Taking that away is unconscionable.”
The proposed change would affect not just breast cancer patients but potentially those battling lung, colon, and ovarian cancers as well—conditions where biomarker testing has become equally indispensable.
the financial reality behind the decision
Behind the scenes, the recommendation reflects a broader tension in American health care: how to balance innovation with affordability. Medicare has been under immense pressure to contain costs, and laboratory testing has been a particular target.
Since 2018, Medicare has reduced payments for nearly 75% of laboratory tests. The Protecting Access to Medicare Act of 2014 (PAMA) fundamentally changed how the program reimburses for clinical diagnostic laboratory tests, shifting to market-based rates that have, in practice, resulted in significant cuts.
Now, biomarker testing appears to be the next domino to fall.
The advisory panel’s rationale, according to sources familiar with the deliberations, centers on what they describe as insufficient evidence that these tests improve long-term patient outcomes. But oncologists counter that the evidence is overwhelming—and that requiring more studies before covering the tests would effectively deny patients access today while researchers spend years collecting additional data.
a familiar pattern of denial
For patient advocates, this decision feels like déjà vu. Similar battles have played out over breast ultrasound screenings, PET scans, and genetic testing for BRCA mutations—each time with patients caught in the crossfire.
Medicare breast cancer screening coverage has historically been a moving target, with beneficiaries often left confused about what’s covered and what isn’t. In recent years, some women have received surprise bills for screenings they believed were fully covered. Now, the stakes are even higher: this isn’t about a screening—it’s about determining the very course of treatment.
“We’re talking about tests that directly influence whether a woman receives chemotherapy or avoids it entirely,” said a breast surgical oncologist based in Chicago. “That’s not a minor decision. That’s the difference between months of debilitating side effects and a treatment plan that respects her quality of life.”
the human cost of coverage denials
Behind every policy debate are real people facing real consequences.
Consider a 72-year-old woman with early-stage, hormone-receptor-positive breast cancer. Her oncologist orders a genomic test to determine her recurrence risk. If the score is low, she can skip chemotherapy and rely on hormone therapy alone. If it’s high, she needs aggressive intervention.
Without Medicare coverage, she faces a choice: pay thousands of dollars she doesn’t have, or proceed with chemotherapy without knowing whether it’s truly necessary. For many, the latter option—enduring toxic treatment that may offer minimal benefit—becomes the only viable path.
That’s not personalized medicine. That’s medicine by financial default.
what happens next
The recommendation is not yet final. CMS will accept public comments before issuing a final coverage determination, and advocates are mobilizing to ensure the agency hears from patients, physicians, and families who would be affected.
Legislative intervention is also possible. Several members of Congress have already signaled interest in preserving access to biomarker testing, and patient advocacy groups are preparing to lobby for statutory protections.
But time is of the essence. For the thousands of women diagnosed with breast cancer each month, delays in coverage decisions translate directly into delays in care.
the broader implications for American health care
This fight extends far beyond breast cancer. It’s a bellwether for how Medicare—and by extension, private insurers—will handle the explosion of precision medicine tools that are transforming oncology.
If biomarker tests become a casualty of cost-cutting, what’s next? Genetic sequencing? Liquid biopsies? The cutting-edge technologies that hold the promise of catching cancers earlier and treating them more effectively?
Breast cancer biomarker testing access isn’t just a niche concern for specialists. It’s a frontline issue in the broader battle over whether American health care will embrace innovation or retreat to the one-size-fits-all approaches of the past.
what patients can do right now
For women currently navigating breast cancer treatment, the uncertainty is deeply unsettling. Oncology practices are already fielding calls from worried patients asking whether their tests will still be covered.
Advocates urge patients to:
- Contact their representatives in Congress to voice support for preserving biomarker testing coverage
- Submit public comments to CMS during the formal comment period
- Talk to their oncology team about financial assistance programs offered by test manufacturers and patient advocacy groups
- Stay informed through reputable patient advocacy organizations like the American Cancer Society and Susan G. Komen
a defining moment for women’s health
This isn’t the first time Medicare coverage decisions have sparked controversy, and it won’t be the last. But the stakes here feel particularly high because biomarker testing has become so embedded in modern cancer care.
New Medicare breast cancer policy changes could have ripple effects across the entire health care system, influencing private insurer decisions and potentially reshaping the standard of care for years to come.
For LeeAnne Loney and countless others like her, the waiting is the hardest part. A test that could guide her treatment decisions hangs in the balance—not because the science is uncertain, but because the finances are.
As one oncologist put it: “We’ve spent twenty years proving these tests save lives. Now we have to spend our energy proving they’re worth paying for. That’s a fight we shouldn’t have to have.
